Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.

Adam S. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University before serving as the Present-Levinson Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York City.

Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases and is a well-recognized leader in the field.  In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 225 articles and chapters on the subject. His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. 

Dr. Cheifetz lectures nationally and internationally on IBD.  Dr. Cheifetz is also actively involved with teaching and mentoring medical students, residents, and fellows and is proud to have trained numerous physicians who now specialize in IBD and direct centers of their own.  In addition, he serves on numerous editorial boards including Journal of Crohn’s and Colitis and the World Journal of Gastroenterology. He is a fellow of the American Gastroenterological Association and American College of Gastroenterology.